|
AME
-- a medical miracle?
a 30-minute documentary video
AME
Amphotericin B Methyl Ester
is a patent free medication to treat HIV/AIDS victims in the Third World. AME is a derivative of
Amphotericin B, a highly effective
medication for treatment of fungal disease.
AME Research Team Includes:
|
Kenneth
R. Reuhl, Ph.D.
Professor of Neurotoxicology
School of Pharmacy
Rutgers University |
Carl P. Schaffner, Ph.D.
Director, AME Research Group
Professor Emeritus
Waksman Institute of Microbiology |
|
 |
|
Eric O. Freed, Ph.D.
Chief, Virus Cell Interaction Section
HIV Drug Resistance Program
National Cancer Institute
National Institutes of Health
|
Samuel Afrane, Ph.D.
Senior Lecturer
Kwame Nkrumah University
of Science and Technology
Kumasi, Ghana, West Africa |
|
The research team headed by Dr. Schaffner includes:
Dr. Robert
Parsons, Basking Ridge, NJ; (the late Dr. Paul Hoeprich, Wilmington, DE
conducted much research in this project until his death); and others.
Africa based team members include: Dr. George Bedu-Addo; Dr. Sampson Agodzo; Dr.
T. C. Fleischer; and Dr. Yao Dwomo-Fokuo.
|
Benefits of AME
• Low cost patent-free medication treatment for HIV/AIDS patients in the
Third World
Medication free of patents, can legally be manufactured by
any company.
Competitive manufacture is the key to lower cost.
• Dual efficacy
In addition to fighting the HIV virus, AME is highly
effective in fighting fungal disease
which claims the lives of many AIDS patients.
• Outpatient treatment from Rural Clinics
This is impossible using parent compound Amphotericin B. Hospitalization is required. |
|
|
Home /
About / Mission
/ Foundation
News / Church
/
Mailing List / Contact
© 2012 ROCK of Africa. All Rights Reserved.
|
|